Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Medical Oncology (2023)
- Medical Education: Yale School Of Medicine (1983) CT
- Fellowship: Stanford University School of Medicine (1991) CA
-
- Residency: Massachusetts General Hospital Internal Medicine Residency (1986) MA
- Internship: Massachusetts General Hospital (1984) MA
- Board Certification: American Board of Internal Medicine, Internal Medicine (1986)
Publications
-
Tissue oxygen distribution in head and neck cancer patients
Adam, M. F., Gabalski, E. C., Bloch, D. A., Oehlert, J. W., Brown, J. M., Elsaid, A. A., 鈥 Terris, D. J. (1999). Tissue oxygen distribution in head and neck cancer patients. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 21(2), 146鈥53. -
Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: Impact on local control
Tate, D. J., Adler, J. R., Chang, S. D., Marquez, S., Eulau, S. M., Fee, W. E., 鈥 Goffinet, D. R. (1999). Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: Impact on local control. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 45(4), 915鈥21. -
In vivo H-1 MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen tension measurements
Star-Lack, J. M., Adalsteinsson, E., Adam, M. F., Terris, D. J., Pinto, H. A., Brown, J. M., & Spielman, D. M. (2000). In vivo H-1 MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen tension measurements. AMERICAN JOURNAL OF NEURORADIOLOGY, 21(1), 183鈥93. -
-
DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
Dorie, M. J., Kovacs, M. S., Gabalski, E. C., Adam, M., Le, Q. T., Bloch, D. A., 鈥 Brown, J. M. (1999). DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia , 1(5), 461鈥67. -
Estimating DNA repair by sequential evaluation of head and neck tumor radiation sensitivity using the comet assay
Terris, D. J., Ho, E. Y., Ibrahim, H. Z., Dorie, M. J., Kovacs, M. S., Le, Q. T., 鈥 Brown, J. M. (2002). Estimating DNA repair by sequential evaluation of head and neck tumor radiation sensitivity using the comet assay. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 128(6), 698鈥702. -
Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas
Le, Q. T., Sutphin, P. D., Raychaudhuri, S., Yu, S. C. T., Terris, D. J., Lin, H. S., 鈥 Giaccia, A. J. (2003). Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. CLINICAL CANCER RESEARCH, 9(1), 59鈥67. -
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients
Le, Q. T., Kovacs, M. S., Dorie, M. J., Koong, A., Terris, D. J., Pinto, H. A., 鈥 Brown, J. M. (2003). Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 56(2), 375鈥83. -
Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma
Le, Q. T., Tate, D., Koong, A., Gibbs, I. C., Chang, S. D., Adler, J. R., 鈥 Goffinet, D. R. (2003). Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 56(4), 1046鈥54. -
Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms
Su, C. K., Mehta, V., Ravikumar, L., Shah, R., PINTO, H., Halpern, J., 鈥 Le, Q. T. (2004). Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 60(1), 171鈥77. -
Long-term results of 100 consecutive comprehensive neck dissections - Implications for selective neck dissections
Sivanandan, R., Kaplan, M. J., Lee, K. J., Lebl, D., PINTO, H., Le, Q. T., 鈥 Fee, W. E. (2004). Long-term results of 100 consecutive comprehensive neck dissections - Implications for selective neck dissections. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 130(12), 1369鈥73. -
Positron-emission tomography for surveillance of head and neck cancer
Ryan, W. R., Fee, W. E., Le, Q. T., & Pinto, H. A. (2005). Positron-emission tomography for surveillance of head and neck cancer. LARYNGOSCOPE, 115(4), 645鈥50. -
Advanced-staged tonsillar squamous carcinoma: Organ preservation versus surgical management of the primary site
Shirazi, H. A., Sivanandan, R., Goode, R., Fee, W. E., Kaplan, M. J., Pinto, H. A., 鈥 Le, Q.-T. (2006). Advanced-staged tonsillar squamous carcinoma: Organ preservation versus surgical management of the primary site. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 28(7), 587鈥94. -
Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas
Le, Q. T., Taira, A. I., Budenz, S., Dorie, M. J., Goffinet, D. R., Fee, W. E., 鈥 Pinto, H. A. (2006). Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. CANCER, 106(9), 1940鈥49. -
Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma
Daly, M. E., Lieskovsky, Y. Y., Pawlicki, T., Yau, J., Pinto, H., Kaplan, M., 鈥 Le, Q.-T. (2007). Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 29(3), 211鈥20. -
Plasma osteopontin is an independent prognostic marker for head and neck cancers
Petrik, D., Lavori, P. W., Cao, H., Zhu, Y., Wong, P., Christofferson, E., 鈥 Le, Q.-T. (2006). Plasma osteopontin is an independent prognostic marker for head and neck cancers. JOURNAL OF CLINICAL ONCOLOGY, 24(33), 5291鈥97. -
Clinical role of F-18-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma
Quon, A., Fischbein, N. J., McDougall, I. R., Le, Q.-T., Loo, B. W., Pinto, H., & Kaplan, M. J. (2007). Clinical role of F-18-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. JOURNAL OF NUCLEAR MEDICINE, 48, 58S鈥67S. -
Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma
Hara, W., Loo, B. W., Goffinet, D. R., Chang, S. D., Adler, J. R., Pinto, H. A., 鈥 Le, Q.-T. (2008). Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71(2), 393鈥400. -
In vivo H-1 magnetic resonance spectroscopy of lactate in patients with Stage IV head and neck squamous cell carcinoma
Le, Q.-T., Koong, A., Lieskovsky, Y. Y., Narasimhan, B., Graves, E., Pinto, H., 鈥 Spielman, D. (2008). In vivo H-1 magnetic resonance spectroscopy of lactate in patients with Stage IV head and neck squamous cell carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 71(4), 1151鈥57. -
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
Fakhry, C., Westra, W. H., Cmelak, S. L. A., Ridge, J. A., Pinto, H., Forastiere, A., & Gillison, M. L. (2008). Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 100(4), 261鈥269. -
CHEMOTHERAPY FOR RECURRENT AND METASTATIC HEAD AND NECK-CANCER
Pinto, H. A., & Jacobs, C. (1991). CHEMOTHERAPY FOR RECURRENT AND METASTATIC HEAD AND NECK-CANCER. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 5(4), 667鈥686. -
INTENSITY-MODULATED RADIOTHERAPY IN THE TREATMENT OF OROPHARYNGEAL CANCER: CLINICAL OUTCOMES AND PATTERNS OF FAILURE
Daly, M. E., Le, Q.-T., Maxim, P. G., Loo, B. W., Kaplan, M. J., Fischbein, N. J., 鈥 Chang, D. T. (2010). INTENSITY-MODULATED RADIOTHERAPY IN THE TREATMENT OF OROPHARYNGEAL CANCER: CLINICAL OUTCOMES AND PATTERNS OF FAILURE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 76(5), 1339鈥46. -
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX
Daly, M. E., Le, Q.-T., Jain, A. K., Maxim, P. G., Hsu, A., Loo, B. W., 鈥 Chang, D. T. (2011). INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 33(1), 103鈥11. -
Head and Neck Cancers
Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., Colevas, D., 鈥 Worden, F. (2011). Head and Neck Cancers. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(6), 596鈥649. -
A Planned Neck Dissection Is Not Necessary in All Patients With N2-3 Head-and-Neck Cancer After Sequential Chemoradiotherapy
Soltys, S. G., Choi, C. Y. H., Fee, W. E., Pinto, H. A., & Le, Q.-T. (2012). A Planned Neck Dissection Is Not Necessary in All Patients With N2-3 Head-and-Neck Cancer After Sequential Chemoradiotherapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 83(3), 994鈥99. -
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer
Chang, K. J., Reid, T., Senzer, N., Swisher, S., Pinto, H., Hanna, N., 鈥 Soetikno, R. (2012). Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. GASTROINTESTINAL ENDOSCOPY, 75(6), 1139-? -
Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence.
Ho, A. S., Tsao, G. J., Chen, F. W., Shen, T., Kaplan, M. J., Colevas, A. D., 鈥 Yao, M. (2013). Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. Cancer, 119(7), 1349鈥56. -
Distant metastases from head and neck squamous cancer: the role of adjuvant chemotherapy.
Pinto, H. A., & Jacobs, C. (1995). Distant metastases from head and neck squamous cancer: the role of adjuvant chemotherapy. Cancer Treatment and Research, 74, 243鈥262. -
Adjuvant and neoadjuvant treatment of head and neck cancers: The next chapter
Jacobs, C., & PINTO, H. (1995). Adjuvant and neoadjuvant treatment of head and neck cancers: The next chapter. SEMINARS IN ONCOLOGY, 22(6), 540鈥552. -
Surgical morbidity of neck dissection after chemoradiotherapy in advanced head and neck cancer
Newman, J. P., Terris, D. J., Pinto, H. A., Fee, W. E., Goode, R. L., & Goffinet, D. R. (1997). Surgical morbidity of neck dissection after chemoradiotherapy in advanced head and neck cancer. ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 106(2), 117鈥122. -
Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers
Gabalski, E. C., Adam, M., PINTO, H., Brown, J. M., Bloch, D. A., & Terris, D. J. (1998). Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers. LARYNGOSCOPE, 108(12), 1856鈥60. -
Management of the clinically positive neck in organ preservation for advanced head and neck cancer
Dagum, P., Pinto, H. A., Newman, J. P., Higgins, J. P., Terris, D. J., Goffinet, D. R., & Fee, W. E. (1998). Management of the clinically positive neck in organ preservation for advanced head and neck cancer. AMERICAN JOURNAL OF SURGERY, 176(5), 448鈥452. -
Head and neck cancer - combined modality therapy and chemotherapy.
Head and neck cancer - combined modality therapy and chemotherapy. (1995). : Brian MC and Carbone PP (Eds), Current Therapy in Hematology-Oncology. Mosby, St. Louis. -
Head and neck cancers.
Head and neck cancers. (1995). Macdonald JS, Haller DG, Mayer RJ (Eds), Manual of Oncologic Therapeutics Third Edition. J.B. Lippincott, Philadelphia. -
Survival analysis of multi-center clinical trial using endoscopy (END) and endoscopic ultrasound (EUS) guided fine needle injection (FNI) of anti-tumor agent (TNFerade (TM) biologic) in patients with locally advanced esophageal cancer
Chang, K., Senzer, N., Soetikno, R., Swisher, S., Reid, T., Mauer, A., 鈥 Forastiere, A. (2008). Survival analysis of multi-center clinical trial using endoscopy (END) and endoscopic ultrasound (EUS) guided fine needle injection (FNI) of anti-tumor agent (TNFerade (TM) biologic) in patients with locally advanced esophageal cancer. Presented at the 73rd Annual Meeting of the American-College-of-Gastroenterology, ORLANDO,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL: NATURE PUBLISHING GROUP. -
Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines
Pfister, D. G., Ang, K.-K., Brizel, D. M., Burtness, B. A., Busse, P. M., Caudell, J. J., 鈥 Hughes, M. (2013). Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(8), 917鈥23. -
Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group
Gilbert, J., Li, Y., Pinto, H. A., JENNINGS, T., Kies, M. S., Silverman, P., & Forastiere, A. A. (2006). Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 28(3), 197鈥204. -
Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group study E2399
Cmelak, A. J., Li, S., Goldwasser, M. A., Murphy, B., Cannon, M., Pinto, H., 鈥 Forastiere, A. A. (2007). Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group study E2399. JOURNAL OF CLINICAL ONCOLOGY, 25(25), 3971鈥77. -
Physician perspectives on increasing minorities in cancer clinical trials: An Eastern Cooperative Oncology Group (ECOG) initiative
Pinto, H. A., McCaskill-Stevens, W., Wolfe, P., & Marcus, A. C. (2000). Physician perspectives on increasing minorities in cancer clinical trials: An Eastern Cooperative Oncology Group (ECOG) initiative. ANNALS OF EPIDEMIOLOGY, 10(8), S78鈥揝84. -
Recruiting minority cancer patients into cancer clinical trials: A pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association
McCaskill-Stevens, W., PINTO, H., Marcus, A. C., Comis, R., Morgan, R., Plomer, K., & Schoentgen, S. (1999). Recruiting minority cancer patients into cancer clinical trials: A pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association. JOURNAL OF CLINICAL ONCOLOGY, 17(3), 1029鈥1039. -
Head and Neck Cancers, Version 2.2014
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., 鈥 Hughes, M. (2014). Head and Neck Cancers, Version 2.2014. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(10), 1454鈥87. -
Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang, C., Chan, C., Jiang, W., Murphy, J. D., von Eyben, R., Colevas, A. D., 鈥 Le, Q.-T. (2015). Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head & Neck, 37(3), 386鈥92. -
Head and Neck Cancers, Version 1.2015.
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., 鈥 Hughes, M. (2015). Head and Neck Cancers, Version 1.2015. Journal of the National Comprehensive Cancer Network , 13(7), 847鈥56. -
Head and Neck Cancers, Version 1.2015 Featured Updates to the NCCN Guidelines
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., 鈥 Hughes, M. (2015). Head and Neck Cancers, Version 1.2015 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(7), 847鈥56. -
Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence
Ho, A. S., Tsao, G. J., Chen, F. W., Shen, T., Kaplan, M. J., Colevas, A. D., 鈥 Yao, M. (2013). Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence. CANCER, 119(7), 1349鈥56. -
NCCN Guidelines (R) Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines
Colevas, A. D., Yom, S. S., Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., 鈥 Darlow, S. D. (2018). NCCN Guidelines (R) Insights Head and Neck Cancers, Version 1.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(5), 479鈥90. -
Double-Blind, Randomized Phase 3 Trial of Low-Dose 13-Cis Retinoic Acid in the Prevention of Second Primaries in Head and Neck Cancer: Long-Term Follow-Up of a Trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590)
Bhatia, A. K., Lee, J.-W., Pinto, H. A., Jacobs, C. D., Limburg, P. J., Rubin, P., 鈥 Pandya, K. J. (2017). Double-Blind, Randomized Phase 3 Trial of Low-Dose 13-Cis Retinoic Acid in the Prevention of Second Primaries in Head and Neck Cancer: Long-Term Follow-Up of a Trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). CANCER, 123(23), 4653鈥62. -
NCCN Guidelines (R) Insights Head and Neck Cancers, Version 2.2017
Adelstein, D., Gillison, M. L., Pfister, D. G., Spencer, S., Adkins, D., Brizel, D. M., 鈥 Darlow, S. D. (2017). NCCN Guidelines (R) Insights Head and Neck Cancers, Version 2.2017. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(6), 761鈥70. -
Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
Trieu, V., Pinto, H., Riess, J. W., Lira, R., Luciano, R., Coty, J., 鈥 Colevas, A. D. (2018). Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. ONCOLOGIST, 23(7), 764-+. -
Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial.
Argiris, A., Li, S., Savvides, P., Ohr, J., Gilbert, J., Levine, M. A., 鈥 Burtness, B. (2017). Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590).
Bhatia, A. K., Leek, J.-W., Pinto, H., Jacobs, C. D., Limburg, P. J., Arusell, R., 鈥 Pandya, K. J. (2016). Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
Argiris, A., Li, S., Savvides, P., Ohr, J. P., Gilbert, J., Levine, M. A., 鈥 Burtness, B. (2019). Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1900555. -
Head and Neck Cancers, Version 2.2020
Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Anzai, Y., Brizel, D. M., 鈥 Darlow, S. D. (2020). Head and Neck Cancers, Version 2.2020. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 18(7), 873鈥98. -
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2022.
Caudell, J. J., Gillison, M. L., Maghami, E., Spencer, S., Pfister, D. G., Adkins, D., 鈥 Darlow, S. D. (2022). NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2022. Journal of the National Comprehensive Cancer Network : JNCCN, 20(3), 224鈥234. -
Recurrent bilateral cutaneous squamous cell carcinoma arising within pretibial hypertrophic lichen planus with metastasis while on cemiplimab
Leeolou, M., Burgren, N., Lee, C., Momeni, A., Pinto, H., Johannet, P., 鈥 Chang, A. L. S. (2022). Recurrent bilateral cutaneous squamous cell carcinoma arising within pretibial hypertrophic lichen planus with metastasis while on cemiplimab. Journal of the American Academy of Dermatology Case Reports. -
Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292).
Kemeny, M. M., Zhao, F., Forastiere, A. A., Catalano, P., Hamilton, S. R., Miedema, B. W., 鈥 Benson, A. B. (2022). Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292). Annals of Surgical Oncology. -
In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation.
Jun, M., Pinto, H., Le, Q.-T. T., Quon, A., Hara, W., Coty, J., 鈥 Colevas, A. D. (2023). In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation. PloS One, 18(2), e0276651. -
MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis.
Khanna, V., Eslami, G., Reyes, R., Diep, R., Fernandez-Pol, S., Stehr, H., 鈥 Chen, C. T. (2025). MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis. NPJ Precision Oncology, 9(1), 34. -
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2025.
Colevas, A. D., Cmelak, A. J., Pfister, D. G., Spencer, S., Adkins, D., Birkeland, A. C., 鈥 Darlow, S. D. (2025). NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2025. Journal of the National Comprehensive Cancer Network : JNCCN, 23(2), 2鈥11.
-
DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
Clinical Trials
Clinical trials are 糖心传媒 studies that evaluate a new medical approach, device, drug, or other treatment. As a 糖心传媒 patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer
- Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
- Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
- Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
- Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
- Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
- Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
- Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
Practice Locations
Head and Neck Cancer Program at 900 Blake Wilbur Palo Alto, CA
Palo Alto, CA
Head and Neck Cancer Program at 900 Blake Wilbur
900 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by 糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of 糖心传媒, 糖心传媒 Tri- Valley, or Stanford Medicine Partners. 糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(54 reviews)
Dr Pinto is just AWESOME!
A physician and specialist of the highest caliber, Dr. Pinto provided the best medical care and advice I could ever expect.
Dr pinto did a great job
He has been a superb professional for my care芒鈧 all I could have asked for ..
Thank you
Dr Harlan Pinto is an excellent and compassionate oncologist. I feel honored to be in his care. I first received his outstanding care in 1994 for terminal cancer.
Dr Pinto is very thorough and pleasant to work with.
Dr. Pinto is always very caring and knows all the current medical discoveries and new drugs for the patients.
Worlds best
It was a pleasant experience!
Dr. Pinto is a knowledgeable and caring doctor. He clearly explains the treatment plan and encourages patients to contact him at any time with concerns or changes in health. He has a positive attitude and always gives the patient as much time as they need.
I couldn't ever imagine how wonderful my Standford team is.
Always appreciate Dr. Pinto's expertise, honest opinions and recommendations relative to my cancer treatment.
Dr Pinto always listens to my inquiries regarding my treatments.He is very caring and is an excellent doctor.
Thanks for Dr. Pinto!
excellent staff and very caring Doctor. We like Dr. Pinto's knowledge and like his positive and encouraging behaviour.Always very caring and supportive.
He is a fine doctor and I was happy to connect with him in this way.
Harlan was good. No complaints about his visit with me. I do not know what was the connection issues on his end. As a Dr I am totally satisfied with him.
Harlan Pinto is one of the most kindest and respectful doctors l have worked with.
He is always on top of my case.
De. Pinto did an excellent job explaining the aspects of what his role would be plus additional information that was important to me!
Overall my dr. was really good.
Dr. Pinto is excellent. He is very concerned about making sure he takes care of you. His PA (Brian) is also excellent.)
Dr. Pinto is very knowledgeable & has provided me info that I do not believe other doctors have. I now have an idea what to look out for a plan for the next few years exp. results of dry mouth on teeth, tightening of jaw opening if not exercised & more.
I am SO FORTUNATE to have Dr. Pinto as my doctor. He is always kind, always listens to me, always encouraging.
Dr. Pinto is the ultimate.
Dr. Pinto & staff are amazing.
Dr. Pinto is one of the finest, most caring doctors I have worked with.
Dr. Pinto has always been friendly, caring & thorough in all my visits for the past 12 yrs! We enjoy visiting w/him on my follow-up care appts.
Dr. Pinto and his PA Ruth are very helpful and welcoming. I feel I'm in very good hands with their care.
Very caring and sorrowful.
I have always considered Dr. Pinto to be an excellent doctor. He is always on top of things, straight forward and thorough. This has always been true with my PAs and NPs.
Dr. Pinto is knowledgeable and I feel confidence with him. He is the best doctor that I have ever met.
Top notch.
Dr. Pinto is knowledgeable. He is nice, experienced and explained every conditions in detail. I feel confidence in him.
Dr. Pinto is admirable in his ability to attend completely to my questions and to answer thoroughly.
Have always felt I was given the best care.
My multi disciplinary appointment was outstanding.
Dr. Kaplan is EXCELLENT.
Ultimate confidence in his knowledge and abilities.
Dr. Pinto has given me an extra year to live already. I'll be looking forward to more years, thanks to Dr. Pinto.
All good.
Dr. Pinto keeps me alive. I believe in him. Some day the cancer may get me, but Dr. Pinto has given me 18 years I did not have in North Dakota.
Have had same provider for 16 yrs. Very comfortable with his opinions and suggestions.
Dr. Pinto is one of the best. The NP who assisted was very good as well.
As always.
Dr. Pinto has a very professional but friendly demeanor, and I like that.
All good.
Excellent - Could not have had a better doctor/糖心传媒.
Good.
Liked Dr. Pinto not his PA.
Dr. Pinto took a long time explaining what needed to be done (Monday) I will have a biopsy on my chest (lungs) & after DNA he can see what will work for my 7 yrs of cancer.
Dr. Pinto is the BEST.
Dr. Pinto is GREAT.
A better representative of Stanford Medical you could not find -
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone:听1-866-742-4811
Fax: 650-320-9443
Monday鈥揊riday, 8 a.m.鈥5 p.m.
Fax: 650-320-9443
Monday鈥揊riday, 8 a.m.鈥5 p.m.
糖心传媒 provides comprehensive services to听refer听and听track patients, as well as the latest information and news for physicians and office staff.听For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
听
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records